YS Biopharma Co (YS Biopharma Co) EV-to-EBITDA : -6.70 (As of May. 19, 2024)

View and export this data going back to 2023. Start your Free Trial

What is YS Biopharma Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, YS Biopharma Co's enterprise value is $224.93 Mil. YS Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-33.57 Mil. Therefore, YS Biopharma Co's EV-to-EBITDA for today is -6.70.

The historical rank and industry rank for YS Biopharma Co's EV-to-EBITDA or its related term are showing as below:

YS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -89.88 Med: -8.71 Max: -4.76
Current: -6.7

During the past 3 years, the highest EV-to-EBITDA of YS Biopharma Co was -4.76. The lowest was -89.88. And the median was -8.71.

YS's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.35 vs YS: -6.70

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-19), YS Biopharma Co's stock price is $0.9779. YS Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569. Therefore, YS Biopharma Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

YS Biopharma Co EV-to-EBITDA Historical Data

The historical data trend for YS Biopharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YS Biopharma Co EV-to-EBITDA Chart

YS Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

EV-to-EBITDA

-15.03

YS Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBITDA	Get a 7-Day Free Trial			-	-	-	-15.03	-

Competitive Comparison of YS Biopharma Co's EV-to-EBITDA

For the Biotechnology subindustry, YS Biopharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

YS Biopharma Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YS Biopharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where YS Biopharma Co's EV-to-EBITDA falls into.

YS Biopharma Co EV-to-EBITDA Calculation

YS Biopharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	224.932	/	-33.571
	=	-6.70

YS Biopharma Co's current Enterprise Value is $224.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YS Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-33.57 Mil.

YS Biopharma Co (NAS:YS) EV-to-EBITDA Explanation

YS Biopharma Co's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.9779	/	-0.569
	=	At Loss

YS Biopharma Co's share price for today is $0.9779.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YS Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

YS Biopharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of YS Biopharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

YS Biopharma Co (YS Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » YS Biopharma Co Ltd (NAS:YS) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.